Low T: The Emerging Opportunity in Direct-to-Consumer Testosterone

Photo | Victor Freitas, Unsplash

By focusing on personalization, transparency, and convenience, direct-to-consumer startups are disrupting the trillion-dollar healthcare industry. From vitamins to fertility tests and even ED pills, you name the product and there’s a company that will ship it to your door.

Next up: direct-to-consumer testosterone could be a billion-dollar opportunity.

  • One study found a fourfold increase in the rate of testosterone use among 18–45-year-old men between 2003 and 2013.
  • The same study said prescriptions for testosterone have risen 300% since 2001.

As men age, their testosterone can drop 1–2% per year after age 30, leading to depression, muscle loss, weight gain, and low libido, among other things. Over time, the wellness industry has introduced a variety of (unproven) “low T” supplements, including multi-vitamins, DHEA, deer antler, pollen, and more. But now, prescription testosterone or testosterone replacement therapy (TRT) is emerging as the go-to option.


As companies like hims and Roman have shown us, playing to our insecurities while also removing the stigma associated with those shortcomings is a formula for success. In the case of low testosterone, creating a direct-to-consumer TRT offering could be an add-on for an existing company or the foundation of a new healthcare startup.

Through a combination of bloodwork and remote consultations with a doctor, it’s not hard to imagine a mail-order TRT service complete with a one-time onboarding (bloodwork) fee, monthly subscription, and upsell opportunities to multivitamins, ED pills, fertility tests, hair loss treatment, and more.

Get the latest health and fitness industry news

Keep up with industry news, trends, investment activity, and job openings — in one weekly newsletter.

    No thanks.